FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to the pharmaceutical industry, specifically to a method of producing a solid and a semi-solid composition. Method of producing a solid or semi-solid composition comprising a step of treating a mixture comprising pancreatin and/or a mixture of digestive enzymes obtained from a mammal, a surface-active component, antioxidant, polymer additives selected from hydrophilic polymers with melting points or glass transition temperatures of 50–160 °C, wherein weight of components in amount of 100 wt. %; ratio of polymer additive to surface-active component ranges from 0.4 (2:5) to 1.5 (3:2); mixture is treated by molding from melt at temperature of 90–130 °C for a period of time from 30 s to 45 min. Solid or semi-solid composition for preventing or treating diseases selected from digestive disorders, pancreatic exocrine insufficiency, pancreatitis, mucoviscidosis, type I and/or type II diabetes. Pharmaceutical composition for preventing or treating diseases selected from digestive disorders, pancreatic exocrine insufficiency, pancreatitis, mucoviscidosis, type I diabetes and/or type II diabetes. Solid or semi-solid composition or pharmaceutical composition for preventing or treating diseases selected from digestive disorders, pancreas exocrine insufficiency, pancreatitis, mucoviscidosis, type I and/or type II diabetes.
EFFECT: method described above enables to reduce undesirable contamination of the composition while maintaining enzymatic activity.
22 cl, 2 dwg, 19 tbl, 60 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOSITION AND DOSAGE FORM CONTAINING SOLID OR SEMISOLID MATRIX | 2006 |
|
RU2423997C9 |
PHARMACEUTICALLY ACCEPTABLE SOLUBILISING COMPOSITION AND PHARMACEUTICAL DOSAGE FORM CONTAINING IT | 2007 |
|
RU2469708C2 |
COMPOSITION CONTAINING FENOFIBRIC ACID OR PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND CAPSULE CONTAINING COMPOSITION | 2008 |
|
RU2500398C2 |
PHARMACEUTICAL DOSED FORM FOR PERORAL INTRODUCTION OF BCL-2 FAMILY INHIBITOR | 2010 |
|
RU2568599C2 |
ANTI-RETROVIRAL COMBINATION | 2014 |
|
RU2675831C2 |
METHOD AND DEVICE FOR PRODUCTION OF SOLID DISPERSION | 2018 |
|
RU2785565C2 |
PHARMACEUTICAL COMPOSITION FOR HIV INFECTION TREATMENT | 2016 |
|
RU2619840C1 |
PHARMACEUTICAL DRUG FORM OF TYROSINE KINASE INHIBITOR FOR PERORAL INTRODUCTION | 2007 |
|
RU2468788C2 |
COMPOSITION CONTAINING PHENOFIBRIN ACID, ITS PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE | 2003 |
|
RU2356549C2 |
PHARMACEUTICAL DOSED FORM, CONTAINING POLYMER CARRIER COMPOSITION | 2009 |
|
RU2519679C9 |
Authors
Dates
2020-01-24—Published
2015-11-05—Filed